GDRX Stock Recent News
GDRX LATEST HEADLINES
GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.
First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif.
Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks is more attractive to value investors?
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference.
The cost of prescription medications in the U.S. has increased by 37% since 2014, far surpassing the rate of inflation, according to data from drug savings company GoodRx. Though the price increases have slowed this year in comparison with the past decade, the average American spends $16.26 out of pocket per prescription, according to the data.
GoodRx aims to give consumers a better handle on prescription affordability. The prescription savings platform introduced its Prescription Cost Tracker to monitor out-of-pocket prescription spending trends in the United States, according to a Wednesday (June 26) press release.
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86819&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) and reminds investors of the June 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.
LOS ANGELES--(BUSINESS WIRE)--GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm.